Rechercher des projets européens

12 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet

 40

 TERMINÉ 
Vancomycin is the critically important antibiotic to treat neonatal Late Onset Sepsis (LOS) due to Gram positive bacteria in neonates, including Coagulase Negative Staphylococci (CoNS) and Staphylococcus aureus. These organisms also create biofilms which are extremely resistant to antibiotics. The increased incidence of LOS due to bacteria such as CoNS and MRSA in NICUs has led to a marked increas ...
Voir le projet

 14

 TERMINÉ 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Voir le projet

 29

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 
Progress in biomedical research and healthcare requires profiting from the huge amount of data and knowledge that are generated. However, most of the potential users have no means to efficiently exploit this wealth of information. Up to now, many of the efforts done for developing bioinformatics methods and applications have not produced the expected societal impact for different reasons, includin ...
Voir le projet

 13

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 
To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be the best option. We have reported in a double-blind placebo controlled study some of the best, most solid data showing that HIV-1 specific immune responses elicited by therapeutic dendritic cell (DC) vaccines pulsed ex vivo with inactivated autologous whole vir ...
Voir le projet

 8

 TERMINÉ 
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet

 30

 TERMINÉ 

Semantic Data Platform for Healthcare (SEMCARE)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2015,

...nd and supply sides. Hospitals in three different European countries serve as pilot sites and have particular interests in applying SEMCARE in their clinical research activities. The SMEs AVERBIS and SYNAPSE have a clear interest in the exploitation of the results. Regarding commercialization, a pharmaceutical partner network that has a genuine interest in supporting the dissemination of our resul ...
Voir le projet

 5

 TERMINÉ 

Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,

"In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated with an increased risk of myocardial infarction, a T2DM complication it was actually supposed to prevent. This example shows several things. First, the approval requirements do not guarantee a longer term positive benefit risk profile. Second, large scale postm ...
Voir le projet

 19

 TERMINÉ 

Genotype-To-Phenotype Databases: A Holistic Solution (GEN2PHEN)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2013,

"The GEN2PHEN project aims to unify human and model organism genetic variation databases towards increasingly holistic views into Genotype-To-Phenotype (G2P) data, and to link this system into other biomedical knowledge sources via genome browser functionality. The project will establish the technological building-blocks needed for the evolution of today’s diverse G2P databases into a future seaml ...
Voir le projet

 23

 TERMINÉ 

Arrhythmogenic potential of drugs (ARITMO)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2013,

The ability of some compounds to prolong the QT interval of the electrocardiogram and to precipitate Torsade de Pointes (TdP, a potentially fatal arrhythmia) has caused several regulatory interventions, including drug withdrawals. Specific guidelines have been implemented to detect QT liability of new compounds as early as possible. However there is growing evidence that an increase in the QT inte ...
Voir le projet

 21